FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers

    NEXT STORY
    PAVmed Subsidiary Lucid Diagnostics Launches World-Class Medical Advisory Board and Appoints Chief Medical Officer
    PREV STORY
    Delcath Joins the Ocular Melanoma Community in Recognizing Rare Disease Day
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    The Alliance for Regenerative Medicine Releases Q1 2018 Data Report, Highlighting Sector Trends and Metrics

    WASHINGTON, D.C., May 10, 2018 (GLOBE NEWSWIRE) --  The Alliance for Regenerative Medicine (ARM) ...

    author_avatar
    NASDAQ Market News

    Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    author_avatar
    NASDAQ Market News

    Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at Karlskoga, Sweden Facility

    EAST RUTHERFORD, N.J., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading ...

    author_avatar
    NASDAQ Market News